- Home
- SGN vs VRAX Comparison
SGN vs VRAX Comparison
Compare SGN & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- VRAX
- Stock Information
- Founded
- SGN 2019
- VRAX 2013
- Country
- SGN United States
- VRAX United Kingdom
- Employees
- SGN N/A
- VRAX N/A
- Industry
- SGN
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SGN
- VRAX Health Care
- Exchange
- SGN Nasdaq
- VRAX Nasdaq
- Market Cap
- SGN 3.8M
- VRAX 4.4M
- IPO Year
- SGN 2023
- VRAX 2022
- Fundamental
- Price
- SGN $1.55
- VRAX $0.78
- Analyst Decision
- SGN
- VRAX Strong Buy
- Analyst Count
- SGN 0
- VRAX 1
- Target Price
- SGN N/A
- VRAX $3.00
- AVG Volume (30 Days)
- SGN 657.8K
- VRAX 117.7K
- Earning Date
- SGN 08-12-2025
- VRAX 01-01-0001
- Dividend Yield
- SGN N/A
- VRAX N/A
- EPS Growth
- SGN N/A
- VRAX N/A
- EPS
- SGN N/A
- VRAX N/A
- Revenue
- SGN $391,126.00
- VRAX $6,331.00
- Revenue This Year
- SGN N/A
- VRAX $217,274.83
- Revenue Next Year
- SGN N/A
- VRAX N/A
- P/E Ratio
- SGN N/A
- VRAX N/A
- Revenue Growth
- SGN N/A
- VRAX N/A
- 52 Week Low
- SGN $0.44
- VRAX $0.72
- 52 Week High
- SGN $36.70
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- SGN 51.32
- VRAX 42.59
- Support Level
- SGN $1.30
- VRAX $0.72
- Resistance Level
- SGN $1.85
- VRAX $0.80
- Average True Range (ATR)
- SGN 0.20
- VRAX 0.07
- MACD
- SGN 0.01
- VRAX -0.01
- Stochastic Oscillator
- SGN 50.82
- VRAX 22.01
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).